(Reuters) - Food and Drug Administration staff said Evista reduces the
risk of invasive breast cancer in certain patients. But they
said they will ask an advisory panel that meets Tuesday to
weigh the benefit against serious risks, such as deep vein
thrombosis, pulmonary embolism and possibly stroke death.
Evista is already approved to treat osteoporosis in women
past menopause. The company is seeking approval to promote the
drug for the reduction in risk of invasive breast cancer in
postmenopausal women with osteoporosis and postmenopausal women
at high risk for breast cancer.
Read more at Reuters.com Government Filings News
risk of invasive breast cancer in certain patients. But they
said they will ask an advisory panel that meets Tuesday to
weigh the benefit against serious risks, such as deep vein
thrombosis, pulmonary embolism and possibly stroke death.
Evista is already approved to treat osteoporosis in women
past menopause. The company is seeking approval to promote the
drug for the reduction in risk of invasive breast cancer in
postmenopausal women with osteoporosis and postmenopausal women
at high risk for breast cancer.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment